WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001026653) V TYPE AND/OR X TYPE sPLA2 INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/026653    International Application No.:    PCT/JP2000/007024
Publication Date: 19.04.2001 International Filing Date: 10.10.2000
Chapter 2 Demand Filed:    09.01.2001    
IPC:
A61K 31/403 (2006.01), A61K 31/404 (2006.01), A61K 31/4045 (2006.01), A61K 31/437 (2006.01), A61K 31/4985 (2006.01), A61K 31/5025 (2006.01), C07D 209/22 (2006.01), C07D 209/88 (2006.01), C07D 405/04 (2006.01), C07D 471/04 (2006.01), C07D 487/04 (2006.01)
Applicants: SHIONOGI & CO., LTD. [JP/JP]; 1-8, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP) (For All Designated States Except US).
ONO, Takashi [JP/JP]; (JP) (For US Only).
UENO, Masahiko [JP/JP]; (JP) (For US Only).
HANASAKI, Kohji [JP/JP]; (JP) (For US Only)
Inventors: ONO, Takashi; (JP).
UENO, Masahiko; (JP).
HANASAKI, Kohji; (JP)
Agent: YAMAUCHI, Hideaki; Shionogi & Co., Ltd., Intellectual Property Department, 12-4, Sagisu 5-chome, Fukushima-ku, Osaka-shi, Osaka 553-0002 (JP)
Priority Data:
11/293273 15.10.1999 JP
Title (EN) V TYPE AND/OR X TYPE sPLA2 INHIBITORS
(FR) INHIBITEURS SPLA2 DU TYPE V ET/OU DU TYPE X
Abstract: front page image
(EN)V type and/or X type sPLA¿2? inhibitors which contain as the active ingredient compounds represented by general formulae (A), (B), (C), prodrugs thereof, pharmaceutically acceptable salts of the same or solvates of the same, wherein R?1¿, R?2¿, R?3¿ and R?4¿ independently represent each hydrogen, a non-interfering substituent, etc.; R?5¿ represents a carbon ring, a heterocycle, etc.; R?6¿ represents hydrogen, C¿1-3? alkyl, etc.; R?A¿ represents -COCONH¿2?, etc.; and R?B¿ represents -CONH¿2?, etc.
(FR)Cette invention se rapporte à des inhibiteurs sPLA¿2? du type V et/ou du type X, qui contiennent comme principe actif des composés représentés par les formules générales (A), (B), (C), à des promédicaments à base de ces inhibiteurs, à des sels ou solvates de ces inhibiteurs acceptables sur le plan pharmaceutique. Dans ces formules, R?1¿, R?2¿, R?3¿ et R?4¿ représentent chacun séparément hydrogène, un substituant ne produisant pas d'interférences, etc.; R?5¿ représente un cycle de carbone, un hétérocycle, etc.; R?6¿ représente hydrogène, alkyle C¿1-3?, etc.; R?A¿ représente -COCONH¿2?, etc.; et R?B¿ représente -CONH¿2?, etc.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)